Novel Treatment For ADHD - Shire And New River Pharmaceuticals Announce FDA Approval Of The First And Only Stimulant Prodrug VYVANSE

... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). [click link for full article] ...